The overexpression of glutamine transporters such as ASCT2 and SN2 observed in malignant CD138+ cells compared to the remainder of their paired bone marrow CD138- mononuclear cells point to their potential as therapeutic targets against glutamine metabolism that are worth investigating in the future in MM models. The gene discussed is SLC38A5; the disease is Miyoshi myopathy.